National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

CMV pp65 peptide
A peptide derived from cytomegalovirus (CMV) internal matrix protein pp65. CMV pp65 peptide antigen is used in recombinant vaccinia virus as an HLA-A-restricted epitope to produce vaccines and specific CD8+ and CD4+ cell responses against CMV infection, a serious complication of allogeneic bone marrow transplantation (BMT). In BMT, CMV infection may be prevented by passive immunization with donor-derived CMV-pp65-specific T-cell clones if provided early post-BMT. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviation:CMV-PEP



Previous:clopidogrel bisulfate, Cloretazine, clotrimazole, CMF regimen, CMV N495 peptide
Next:CMVpp65-A*0201 peptide vaccine, CNGRC peptide-TNF alpha conjugate, Co-Rax, Cocculus/nux vomica/tabacum/petroleum extract, codeine phosphate

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov